SCHEMBL1359624

SCHEMBL1359624

[c]1noc(-c2cccs2)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 15/20 0.44
NPC1 O15118 13/20 0.44
SMN1; SMN2 Q16637 12/20 0.44
NPSR1 Q6W5P4 2/20 0.44
ALDH1A1 P00352 11/20 0.41
L3MBTL1 Q9Y468 3/20 0.41
TP53 P04637 2/20 0.41
MAPK1 P28482 2/20 0.41
NFKB1 P19838 2/20 0.41
NFKB2 Q00653 2/20 0.41
RELA Q04206 2/20 0.41
LMNA P02545 1/20 0.41
KDM4E B2RXH2 10/20 0.41
HPGD P15428 7/20 0.41
HSD17B10 Q99714 4/20 0.41
TDP1 Q9NUW8 3/20 0.41
MAPT P10636 3/20 0.41
CYP1A2 P05177 2/20 0.41
CYP2D6 P10635 2/20 0.41
CYP2C9 P11712 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9454334 0.69 ALDH1A1 (0.44) RAB9ANPC1SMN1; SMN2NPSR1ALDH1A1
SCHEMBL13762461 0.69 KDM4E (0.70) RAB9ANPC1SMN1; SMN2NPSR1ALDH1A1
SCHEMBL795461 0.67 NPC1 (0.44) RAB9ANPC1SMN1; SMN2ALDH1A1TP53
SCHEMBL733957 0.67 ALDH1A1 (0.49) RAB9ANPC1SMN1; SMN2NPSR1ALDH1A1
SCHEMBL262283 0.67 RAB9A (0.45) RAB9ANPC1SMN1; SMN2NPSR1ALDH1A1
SCHEMBL3475309 0.65 TP53 (0.46) RAB9ANPC1SMN1; SMN2NPSR1ALDH1A1
SCHEMBL9454056 0.65 RAB9A (0.41) RAB9ANPC1SMN1; SMN2NPSR1ALDH1A1
SCHEMBL3619389 0.65 RAB9A (0.44) RAB9ANPC1SMN1; SMN2NPSR1ALDH1A1
SCHEMBL1173378 0.65 TDO2 (0.40) RAB9ANPC1SMN1; SMN2NPSR1ALDH1A1
SCHEMBL10626253 0.65 ALDH1A1 (0.69) RAB9ANPC1SMN1; SMN2NPSR1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120165327-A1 SPIROPIPERIDINES FOR USE AS TRYPTASE INHIBITORS COSTANZO MICHAEL J (US) 2012-06-28 US claimed
US-8158792-B2 Spiropiperidines for use as tryptase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2012-04-17 US claimed
EP-2224803-A1 SPIROPIPERIDINES FOR USE AS TRYPTASE INHIBITORS Janssen Pharmaceutica N.V. (BE) 2010-09-08 EP claimed
US-20090163527-A1 Spiropiperidines for use as tryptase inhibitors JANSSEN PHARMACEUTICA, NV (BE) 2009-06-25 US claimed
WO-2009067202-A1 SPIROPIPERIDINES FOR USE AS TRYPTASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2009-05-28 WO claimed
EP-1885709-A2 BENZOFURAN DERIVATIVES WITH THERAPEUTIC ACTIVITIES Pharmos Corporation (US) 2008-02-13 EP claimed
WO-2006129318-A2 BENZOFURAN DERIVATIVES WITH THERAPEUTIC ACTIVITIES PHARMOS CORPORATION (US) 2006-12-07 WO claimed
US-20210139453-A1 (HETERO)ARYL SULFONAMIDE COMPOUND AND FORMULATION FOR CONTROLLING HARMFUL ORGANISMS NIPPON SODA CO., LTD. (JP) 2021-05-13 US disclosed
EP-3778574-A1 (HETERO)ARYLSULFONAMIDE COMPOUND AND PEST CONTROL AGENT Nippon Soda Co., Ltd. (JP) 2021-02-17 EP disclosed
US-8536189-B2 Spiropiperidines for use as tryptase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2013-09-17 US disclosed
US-8309579-B2 N-hydroxyamide derivatives and use thereof MERCK SERONO SA (CH) 2012-11-13 US disclosed
US-8247437-B2 N-hydroxyamide derivatives and use thereof MERCK SERONO SA (CH) 2012-08-21 US disclosed
US-20120165327-A1 SPIROPIPERIDINES FOR USE AS TRYPTASE INHIBITORS COSTANZO MICHAEL J (US) 2012-06-28 US disclosed
EP-1771421-B1 N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF SERONO LAB (CH) 2009-04-29 EP disclosed
US-20080275060-A1 N-Hydroxyamide Derivatives and Use Thereof LABORATOIRES SERONO SA (CH) 2008-11-06 US disclosed
EP-1951687-A1 N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF Laboratoires Serono SA (CH) 2008-08-06 EP disclosed
US-20080021028-A1 N-Hydroxyamide Derivatives and Use Thereof APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) 2008-01-24 US disclosed
WO-2007060132-A1 N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF LABORATOIRES SERONO S.A. (CH) 2007-05-31 WO disclosed
EP-1771421-A1 N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF Applied Research Systems ARS Holding N.V. (AN) 2007-04-11 EP disclosed
WO-2006010751-A1 N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2006-02-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120165327-A1 SPIROPIPERIDINES FOR USE AS TRYPTASE INHIBITORS TPSAB1, TPSB2, TPSD1 RAB9A 2884/4885NPC1 1407/4885SMN1; SMN2 4323/4885
US-20090163527-A1 Spiropiperidines for use as tryptase inhibitors TPSAB1, TPSB2, TPSD1 RAB9A 2884/4885NPC1 1407/4885SMN1; SMN2 4323/4885
US-20080021028-A1 N-Hydroxyamide Derivatives and Use Thereof HCAR2, HNMT, HPGD RAB9A 2780/4885NPC1 655/4885SMN1; SMN2 1306/4885
US-20080275060-A1 N-Hydroxyamide Derivatives and Use Thereof HNMT, HCAR2, HPGD RAB9A 2765/4885NPC1 641/4885SMN1; SMN2 1322/4885
US-20210139453-A1 (HETERO)ARYL SULFONAMIDE COMPOUND AND FORMULATION FOR CONTROLLING HARMFUL ORGANISMS ARSA, NAT1, SUB1 RAB9A 504/4885NPC1 1340/4885SMN1; SMN2 3093/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.